People

Dr. Hasan Zeytin

After graduating from Trakya University Faculty of Medicine in 1991, Dr. Hasan Zeytin completed his doctoral studies in the Department of Microbiology and Immunology at the University of Kentucky in 2000 on DNA vaccines and cancer immunotherapy studies. He completed his postdoctoral studies at the US National Cancer Institute on anti-cancer immunotherapy strategies and gene therapies.

He decided to return to Turkey in 2003 to continue his career at Nobel Pharmaceuticals. He took part in many different fields at Nobel İlaç, from business development to clinical studies, and held various positions from medical director to executive board member, and coordinated Nobel İlaç's biotechnological drug production investment project.

Within the scope of this investment, he played an important role in the establishment of Turkey's largest ecosystem with mammalian cell-based biotechnological drug R&D and production infrastructure. In this facility, he undertook the management of the development, production and human testing studies of the Virus-Like Particle (VLP) vaccine, one of the Covid-19 vaccines produced in Turkey.

Dr. Hasan Zeytin started to work as the CEO of CinnaGen İlaç San ve Tic AŞ in April 2023.

In addition to making a wide variety of scientific publications, Dr. Zeytin has participated in various international events and made speeches on pharmaceutical markets, biosimilars and clinical studies.